Laboratorios Farmaceuticos Rovi, S.A.

MCE:ROVI.MC

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

Spain

Market Cap

USD 3.25 B

Share Price

USD 63.47

Avg Daily Volume

114,249

Change (1 day)

1.76%

Change (1 year)

-30.41%

Change (YTD)

-2.63%

Laboratorios Farmaceuticos Rovi, S.A. Total Assets for the year ending December 31, 2024: USD 861.55 M

Laboratorios Farmaceuticos Rovi, S.A. Total Assets is USD 861.55 M for the year ending December 31, 2024, a -2.42% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.

Laboratorios Farmaceuticos Rovi, S.A. Total Assets for the year ending December 31, 2023 was USD 882.87 M, a -6.09% change year over year.
Laboratorios Farmaceuticos Rovi, S.A. Total Assets for the year ending December 31, 2022 was USD 940.16 M, a 12.72% change year over year.
Laboratorios Farmaceuticos Rovi, S.A. Total Assets for the year ending December 31, 2021 was USD 834.04 M, a 18.86% change year over year.
Laboratorios Farmaceuticos Rovi, S.A. Total Assets for the year ending December 31, 2020 was USD 701.72 M, a 22.32% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Assets	Accounts Payable	Short-Term Debt	Long-Term Debt

MCE: ROVI.MC

Laboratorios Farmaceuticos Rovi, S.A.

CEO	Mr. Juan Lopez-Belmonte Encina
IPO Date	Dec. 5, 2007
Location	Spain
Headquarters	Calle José Isbert, 2
Employees	2,197
Sector	🏥 Health Care
Industries Clinical Trials 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán to treat attention deficit hyperactivity disorder in children and teenagers. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT Exprès that are contrast injection systems and compatible disposable material. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.